Skip to main content


18-10-2023 | Type 1 diabetes | News

Automated insulin delivery benefits type 1 diabetes individuals at high hypoglycemia risk

Automated insulin delivery reduces hypoglycemia in people with type 1 diabetes at increased risk, improving their time spent in target glucose range.

05-10-2023 | Type 2 diabetes | News

ONWARDS 5: Weekly insulin icodec with app shows real-world promise for type 2 diabetes

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

02-06-2023 | Type 1 diabetes | News

Pregnancy-specific closed-loop system proves feasible for home use

Results of a pilot study show that a hybrid closed-loop insulin delivery system customized for pregnancy used by women with type 1 diabetes at home significantly improved their glucose outcomes.

26-05-2023 | Type 2 diabetes | News

Common antidiabetic add-on therapies offer similar renal outcomes

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

05-05-2023 | Insulin icodec | News

ONWARDS 2: Weekly insulin icodec superior to degludec in type 2 diabetes

The results of ONWARDS 2 show significantly improved glycemic control with weekly insulin icodec versus daily insulin degludec, without significantly increased hypoglycemia, in people with type 2 diabetes.

Pregnancy with insulin pen

10-01-2023 | Pregnancy | News

EXPECT: Degludec noninferior to detemir in pregnancy for type 1 diabetes

Pregnant women with type 1 diabetes can achieve similar glucose control regardless of whether they use insulin degludec or detemir, show the results of the randomised EXPECT trial.

16-12-2022 | Diet | News

Intermittent fasting feasible with insulin-treated type 2 diabetes

A randomized trial reveals benefits of intermittent fasting, without an increased risk for severe hypoglycemia, in people with insulin-treated type 2 diabetes.

Syringe and pills

01-11-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.